New Study Confirms HeartFlow FFRCT Leads to Improved Patient Outcomes
University Hospitals Harrington Heart & Vascular Institute first to adopt technology in U.S.
Stay updated with breaking news from Prospective Randomized Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
University Hospitals Harrington Heart & Vascular Institute first to adopt technology in U.S.
Using coronary computed tomography angiography (CCTA) with HeartFlow’s FFRCT Analysis to evaluate suspected coronary artery disease (CAD) offers more accurate non-invasive diagnosis, fewer unnecessary tests, and higher confidence in identifying patients needing treatment
12 month data from The PRECISE Trial, the first global, prospective, randomized trial comparing diagnosis and evaluation pathways for stable chest pain, will be presented at the AHA 2022 Scientific Sessions.